leadf
logo-loader
AIM:IXI

IXICO PLC

Receive alerts
Market:
AIM
Market Cap:
£55.33 m
Price
117.50 GBX
Change
3.52%
52 weeks high
120.00
52 weeks low
41.50

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the advancement of investigational therapies for neurological diseases through the application of medical image analysis and digital health data analytics, bringing safe and effective treatment to patients sooner. 

We deliver specialist data analytics services that identify and measure unique biomarkers from brain scan and wearable biosensor data produced in clinical research programmes. The results we deliver support our clients in their clinical decisions to align patient selection, protect patient safety and assess disease progression and drug efficacy.  

Our neuroimaging and digital biomarkers are powering some of the most important clinical trials in neuroscience today. IXICO is also collaborating with partners and developing new analytical techniques and companion digital health products to impact patient outcomes.

Our Values


Ability
Ability reflects the value we derive from the diverse skills and experience of our colleagues. We challenge ourselves to continually develop our abilities, to deliver greater value to our stakeholders

Agility
Agility is the ability to rapidly adapt to change. As a growing company, our people thrive on change and the opportunities that this presents to delight our clients in their clinical development programmes

Accountability
Accountability is underpinned by reliability and personal responsibility. At IXICO, we take ownership of our work and understand its impact on our clients’ clinical development programmes.

Aspiration
Aspiration drives us to set ambitious goals. It combines the desire to make things better with the commitment to make it happen. At IXICO, we are proud to be part of the effort to bring life changing treatments to patients sooner and demonstrate this value in our commitment to our clients’ success.

 

 

 

 

Technology

We offer an extensive range of neuroimaging analyses tools for patient stratification/clinical trial enrichment, assessment of eligibility, safety, and efficacy, including radiological reads, structural & advanced MRI, and PET and SPECT analysis.

Combining the best wearable technology together with our digital platform and our scientific and regulatory expertise, we work with clients to discover and clinically validate new digital biomarkers for deployment in clinical trials.

Innovation and AI

Image biomarkers

Digital biomarkers

Data Platforms

United Kingdom, Europe, United States

Charles Spicer

NON-EXECUTIVE CHAIRMAN

Charles joined the Board of IXICO in 2013. He is an experienced Director of, and adviser to, public and private companies primarily in the medtech and life science sectors. He is Non-Executive Chairman of Realm Therapeutics plc, Creo Medical Group plc and 11 Health Technologies Limited and chairs the UK Department of Health Invention for Innovation Funding Panel.

Giulio Cerroni

CHIEF EXECUTIVE OFFICER

Giulio joined IXICO as Chief Executive Officer in February 2017. He has over 30 years of experience in the life sciences sector and a track record of growing business operations in Europe, the US and Asia. Prior to IXICO, Giulio held global leadership roles at ThermoFisher Scientific and the LGC Ltd, where he transformed the scale of LGC’s Genomics division, completing 3 acquisitions in under 18 months. Giulio was a member of the executive leadership responsible for the successful sale of the LGC Ltd to global investment firm, KKR & Co. Inc.

Grant Nash

CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY

Grant joined IXICO as Chief Finance Officer in April 2019. Grant has worked in the life sciences sector for over 15 years. In his executive director role, Grant leads the Company's Finance, Legal and IT functions. Grant joined IXICO from UK Biobank, an international health research data resource, where he had been Finance Director since 2014. Previous to this he was SVP Finance at Evotec, the early stage drug discovery CRO.

Mark Warne

NON-EXECUTIVE DIRECTOR

Mark joined the Board of IXICO in 2016. Mark is Chief Executive Officer of DeepMatter Group plc. Mark is widely recognised in the UK and international life sciences sector, having spent almost 10 years at IP Group Plc, a leading intellectual property commercialisation company, where he led the Healthcare team. Mark is a Non-Executive Director of Open Orphan plc. Mark chairs the Remuneration Committee and is a member of the Audit Committee.

John Bradshaw

NON-EXECUTIVE DIRECTOR

John is a chartered accountant with more than 20 years’ experience as a Chief Financial Officer with venture capital-backed and listed companies. He is the Chief Financial Officer of Syncona Investment Management Limited, the Investment Manager of Syncona Limited. He is a Non-Executive Director and Audit Committee Chair of Creo Medical plc. John joined the board of IXICO in 2013 as a Non-Executive Director and is Chair of the Audit Committe and a member of the Remuneration Committee.

 

IXICO plc

Address:
4th Floor
Griffin Court
15 Long Lane
London
EC1A 9PN

Investor relations:

[email protected]

Cenkos Securities PLC
6-8 Tokenhouse Yard, London EC2R 7AS
T +44 (0)203 7397 8900
W www.cenkos.com

Company Information
IXICO plc is incorporated and registered in England and Wales with registered number 03131723.

The Group operates from its headquarters in London, UK.

Registered Office
4th Floor, Griffin Court, 15 Long Lane, London EC1A 9PN

Registrar

Equiniti Registrars Limited
Aspect House, Spencer Road, Lancing, West Sussex, BN99 6DA
T +44 (0)871 384 2030
W www.equiniti.com

Chartered accountants and statutory auditors
Grant Thornton UK LLP
101 Cambridge Science Park, Milton Road, Cambridge CB4 0FY
T +44 (0)1223 225600
W www.grantthornton.co.uk

Legal advisers
Bristows LLP
100 Victoria Embankment, London, EC4Y 0PH
T +44 (0)20 7400 8000
W www.bristows.com

Financial public relations

Optimum Strategic Communications
The Spice Building, 8 Devonshire Square, London, EC2M 4PL
T +44 (0)203 950 9144
W www.optimumcomms.com

Shareholder information

 
 
 

Directors and their interests

Director's name Number of shares held Percentage %
Charles Spicer 333,196 0.71
Giulio Cerroni 109,600 0.23
John Bradshaw 35,500 0.08
Mark Warne 5,400 0.01

 

Company Information
IXICO plc is incorporated and registered in England and Wales with registered number 03131723.

The Group operates from its headquarters in London, UK.

Registered Office
4th Floor, Griffin Court, 15 Long Lane, London EC1A 9PN

Advisers
Nominated adviser and broker

Advisor & Broker

Cenkos Securities PLC
6-8 Tokenhouse Yard, London EC2R 7AS
T +44 (0)203 7397 8900
W www.cenkos.com

Registrar
Equiniti Registrars Limited
Aspect House, Spencer Road, Lancing, West Sussex, BN99 6DA
T +44 (0)871 384 2030
W www.equiniti.com

Chartered accountants and statutory auditors
Grant Thornton UK LLP
101 Cambridge Science Park, Milton Road, Cambridge CB4 0FY
T +44 (0)1223 225600
W www.grantthornton.co.uk

Legal advisers
Bristows LLP
100 Victoria Embankment, London, EC4Y 0PH
T +44 (0)20 7400 8000
W www.bristows.com

Optimum Strategic Communications
The Spice Building, 8 Devonshire Square, London, EC2M 4PL
T +44 (0)203 950 9144
W www.optimumcomms.com